United States · Biotechnology
Pharmaceuticals
Biotechnology
Healthcare
Stemline Therapeutics, Inc. is dedicated to developing and providing innovative therapies for patients with advanced breast cancer. Their flagship product, ORSERDU (elacestrant), is a prescription medicine designed for postmenopausal women and adult men with ER-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer. ORSERDU is specifically formulated for patients whose disease has progressed after endocrine therapy, offering a targeted treatment option for this challenging condition.
2022
Founded
Biotechnology
Industry
United States
Location
597,124,694
Ranking
0 employees
Size
Get full access to view complete information
Pubrio glocalizes business, people, and intent data from 50+ local sources into one global graph, giving AI and revenue teams full‑market visibility.
